
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.

Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.

FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.

For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.

Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.

Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.

Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.

Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.

Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.

A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.

Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.

IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.

Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.

Kwaku Osei, OD, PhD, FAAO, discussed patient-reported outcomes with a senofilcon C (Johnson & Johnson; Acuvue Vita), reusable lens, with the majority of wearers rating comfort, vision, and handling favorably.

Andrew Pucker, OD, PhD, FAAO, FSLS, FBCLA, discussed how oculomics research presented at AAOpt 2026 could eventually support point-of-care diagnosis and referral decisions.

Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.

A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.

Jacob Lang, OD, FAAO, details his AAOPt 2026 poster presentation "Rapid and Durable Redness Relief with a Novel Brimonidine Tartrate Ophthalmic Solution Containing Hyaluronic Acid."

Amber Carissa "A.C." Flynn details a case in her AAOpt 2026 poster that demonstrates successful ocular surface optimization for a patient with several eye conditions.

Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.

Maria Sampalis, OD, discusses her implementation of the EHR software Barti in her practice.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."

Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.

Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.

A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.